Mesoblast Limited (MSB:ASX)


right-arrow Created with Sketch. -0.02 (-0.83%)
MCAP $1.404B
Last trade 16.10pm 27/01/2021 20mins delayed

Latest Announcements

12/01/2021MSBMesoblast Limited
12/01/2021MSBMesoblast Limited
11/01/2021 Price SensitivePSMSBMesoblast Limited
18/12/2020MSBMesoblast Limited
18/12/2020 Price SensitivePSMSBMesoblast Limited
16/12/2020 Price SensitivePSMSBMesoblast Limited
16/12/2020 Price SensitivePSMSBMesoblast Limited
15/12/2020 Price SensitivePSMSBMesoblast Limited

Company Overview

Mesoblast Limited is engaged in the development of regenerative medicine products. The Company’s regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high and unmet medical needs. The Company’s portfolio of Phase III product candidates comprises RYONCIL (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD), REVASCOR for advanced chronic heart failure (CHF) and MPC-06-ID for chronic low back pain due to degenerative disc disease. The Company's product candidate, MPC-150-IM, is in Phase III trials for the treatment of both advanced and end-stage CHF. The Company has conducted Phase II trial of MPC-300-IV in patients with biologic-refractory rheumatoid arthritis. The Company is developing MPC-25-Osteo for spinal fusion.

MSB in the news

Search Previous Announcements